$27.88
Insights on Royalty Pharma Plc
Revenue is down for the last 2 quarters, 596.0M → 567.97M (in $), with an average decrease of 4.7% per quarter
Netprofit is down for the last 2 quarters, 494.34M → 4.77M (in $), with an average decrease of 99.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.2% return, outperforming this stock by 75.6%
In the last 3 years, Novo Nordisk A/s has given 234.2% return, outperforming this stock by 266.2%
0.16%
Downside
Day's Volatility :1.19%
Upside
1.03%
9.72%
Downside
52 Weeks Volatility :24.69%
Upside
16.58%
Period | Royalty Pharma Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -5.72% | 0.4% | 0.0% |
6 Months | 6.33% | 14.0% | 0.0% |
1 Year | -15.11% | 11.6% | -0.3% |
3 Years | -32.02% | 18.6% | -20.6% |
Market Capitalization | 16.9B |
Book Value | $14.41 |
Dividend Share | 0.81 |
Dividend Yield | 2.98% |
Earnings Per Share (EPS) | 1.78 |
PE Ratio | 15.85 |
PEG Ratio | 1.18 |
Wall Street Target Price | 45.33 |
Profit Margin | 35.69% |
Operating Margin TTM | -12.99% |
Return On Assets TTM | 3.54% |
Return On Equity TTM | 12.06% |
Revenue TTM | 2.2B |
Revenue Per Share TTM | 4.99 |
Quarterly Revenue Growth YOY | -17.0% |
Gross Profit TTM | 1.3B |
EBITDA | 1.5B |
Diluted Eps TTM | 1.78 |
Quarterly Earnings Growth YOY | -0.99 |
EPS Estimate Current Year | 3.94 |
EPS Estimate Next Year | 4.39 |
EPS Estimate Current Quarter | 0.98 |
EPS Estimate Next Quarter | 0.96 |
What analysts predicted
Upside of 62.59%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 12.33% |
Net Income | 1.4B | ↑ 13.86% |
Net Profit Margin | 76.76% | ↑ 1.04% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 1.08% |
Net Income | 2.3B | ↑ 70.46% |
Net Profit Margin | 129.45% | ↑ 52.69% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 16.96% |
Net Income | 495.2M | ↓ 78.91% |
Net Profit Margin | 23.34% | ↓ 106.11% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | ↑ 7.89% |
Net Income | 478.8M | ↓ 3.32% |
Net Profit Margin | 20.91% | ↓ 2.43% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↓ 2.28% |
Net Income | 42.8M | ↓ 91.05% |
Net Profit Margin | 1.91% | ↓ 19.0% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 5.24% |
Net Income | 1.1B | ↑ 2549.5% |
Net Profit Margin | 48.2% | ↑ 46.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 565.7M | ↓ 1.35% |
Net Income | -610.2M | ↓ 380.11% |
Net Profit Margin | -107.85% | ↓ 145.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 684.0M | ↑ 20.9% |
Net Income | 340.8M | ↓ 155.85% |
Net Profit Margin | 49.82% | ↑ 157.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 538.2M | ↓ 21.31% |
Net Income | 227.6M | ↓ 33.2% |
Net Profit Margin | 42.29% | ↓ 7.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 536.3M | ↓ 0.35% |
Net Income | 72.1M | ↓ 68.32% |
Net Profit Margin | 13.45% | ↓ 28.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 596.0M | ↑ 11.13% |
Net Income | 494.3M | ↑ 585.5% |
Net Profit Margin | 82.94% | ↑ 69.49% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 568.0M | ↓ 4.7% |
Net Income | 4.8M | ↓ 99.03% |
Net Profit Margin | 0.84% | ↓ 82.1% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 11.4B | - |
Total Liabilities | 6.8B | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 12.4B | ↑ 9.5% |
Total Liabilities | 6.3B | ↓ 7.47% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 21.1B | ↑ 69.46% |
Total Liabilities | 6.1B | ↓ 2.92% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 17.5B | ↓ 16.97% |
Total Liabilities | 7.3B | ↑ 18.67% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 16.8B | ↓ 4.01% |
Total Liabilities | 7.3B | ↑ 0.29% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 16.4B | ↓ 2.57% |
Total Liabilities | 6.3B | ↓ 13.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 16.8B | ↓ 4.86% |
Total Liabilities | 7.3B | ↑ 0.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 17.1B | ↑ 1.55% |
Total Liabilities | 7.3B | ↓ 0.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 17.1B | ↑ 0.28% |
Total Liabilities | 7.3B | ↑ 0.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.9B | ↓ 7.39% |
Total Liabilities | 6.3B | ↓ 14.2% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 16.4B | ↑ 3.32% |
Total Liabilities | 6.3B | ↑ 0.43% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 16.1B | ↓ 1.53% |
Total Liabilities | 6.3B | ↓ 0.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 14.1% |
Investing Cash Flow | 303.4M | ↓ 119.11% |
Financing Cash Flow | -1.4B | ↑ 1018.91% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↑ 3.02% |
Investing Cash Flow | -2.2B | ↓ 809.77% |
Financing Cash Flow | -1.2B | ↓ 13.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↑ 22.04% |
Investing Cash Flow | -2.8B | ↑ 28.12% |
Financing Cash Flow | 1.5B | ↓ 224.79% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↓ 0.84% |
Investing Cash Flow | -1.9B | ↓ 32.22% |
Financing Cash Flow | 385.1M | ↓ 74.1% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 6.27% |
Investing Cash Flow | -1.0B | ↓ 44.96% |
Financing Cash Flow | -944.9M | ↓ 345.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 569.9M | ↑ 5.77% |
Investing Cash Flow | 414.7M | ↓ 129.1% |
Financing Cash Flow | -265.6M | ↑ 15.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.0B | ↑ 81.4% |
Investing Cash Flow | -558.5M | ↓ 234.67% |
Financing Cash Flow | -210.4M | ↓ 20.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 607.8M | ↓ 41.21% |
Investing Cash Flow | -63.4M | ↓ 88.64% |
Financing Cash Flow | -347.0M | ↑ 64.94% |
Sell
Neutral
Buy
Royalty Pharma Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Royalty Pharma Plc | 2.73% | 6.33% | -15.11% | -32.02% | -36.61% |
Moderna, Inc. | 24.35% | 68.6% | 3.16% | -19.55% | 450.13% |
Regeneron Pharmaceuticals, Inc. | 8.55% | 21.91% | 30.49% | 86.78% | 220.79% |
Novo Nordisk A/s | 6.83% | 35.3% | 59.23% | 234.23% | 468.67% |
Vertex Pharmaceuticals Incorporated | 11.29% | 24.82% | 28.22% | 102.21% | 159.28% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Royalty Pharma Plc | 15.77 | 15.77 | 1.18 | 3.94 | 0.12 | 0.04 | 0.03 | 14.41 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.07 | 29.07 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.14 | 46.14 | 2.36 | 3.46 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 27.78 | 27.78 | 0.53 | 17.1 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Royalty Pharma Plc | Buy | $17.0B | -36.61% | 15.77 | 35.69% |
Moderna, Inc. | Buy | $49.2B | 450.13% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $107.6B | 220.79% | 29.07 | 29.45% |
Novo Nordisk A/s | Buy | $589.9B | 468.67% | 46.14 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $110.9B | 159.28% | 27.78 | 39.46% |
Morgan Stanley - Brokerage Accounts
Vanguard Group Inc
FMR Inc
BlackRock Inc
Baillie Gifford & Co Limited.
Adage Capital Partners Gp LLC
In the quarter ending March,2024. Royalty Pharma Plc has declared dividend of $0.21
Read Moreroyalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Organization | Royalty Pharma Plc |
Employees | 0 |
CEO | Mr. Pablo Gerardo Legorreta |
Industry | Health Technology |
Microsectors Energy 3x Inverse Leveraged Notes Due January 29 2043
$27.88
-1.17%
Lkq Corp.
$27.88
-1.17%
Citigroup Inc.
$27.88
-1.17%
Southwest Airlines Co.
$27.88
-1.17%
Zillow Group, Inc. - Class C Shares
$27.88
-1.17%
Banco De Chile
$27.88
-1.17%
Cms Energy Corp
$27.88
-1.17%
Philip Morris International, Inc.
$27.88
-1.17%
Celanese Corporation
$27.88
-1.17%